Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

November 7, 2022

https://www.globenewswire.com/news-release/2022/11/07/2549688/0/en/Lyell-Immunopharma-Presents-New-Data-at-SITC-Highlighting-its-Growing-Pipeline-of-T-Cell-Reprogramming-Technologies-and-Product-Candidates-Targeting-Solid-Tumors.html

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq:LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, is presenting preclinical data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on its product candidates and new genetic and epigenetic reprogramming technologies. This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.

Read more at globenewswire.com

Related news for (LYEL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.